Finland· FI-REL-REL44738

Daklinza

A daclatasvir product containing daclatasvir dihydrochloride, registered in Finland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 3 of our 19 countries.

ATC J05AP07

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedDaklinzaATCJ05AP07REGISTER NO.FI-REL-REL44738PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Daclatasvir is registered in 3 of 19 countries.

Countries holding a registration under ATC J05AP07 (daclatasvir), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 1 of them publish a price we can compare per daily dose

Daclatasvir · ATC J05AP07

3 / 19 countries

  • Finlandprice
  • Netherlands
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Daclatasvir dihydrochloride
Manufacturer
Bristol-Myers Squibb Pharma EEIG
Country
Finland (FI)
ATC code
J05AP07
ATC class
Daclatasvir
Defined daily dose
60 mg, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

123 interactions on record for daclatasvir.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Daclatasvir · interactions on record

123 records

  • 21 severe
  • 97 moderate
  • 5 minor

Most severe, free to view

  • EluxadolineA07DA06severe
  • EdoxabanB01AF03severe
  • DexamethasoneH02AB02severe
  • KetoconazoleH02CA03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Daclatasvir in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All daclatasvir products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c444d525-a86b-40eb-b1ff-4d309224a185
GET /v1/drugs/c444d525-a86b-40eb-b1ff-4d309224a185?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "60",
  "form": "tabletti, kalvopäällysteinen",
  "route": "Suun kautta",
  "ddd_unit": "mg",
  "strength": "30 mg",
  "atc_label": "daklatasviiri",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/14/939/001-002",
  "fimea_rel_id": "REL44738",
  "authorised_at": "2014-08-22"
}

See everything about daclatasvir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.